Physician profile
Jonathan Dinh
NPI 1710089081
$4,172.72
in general payments reported to CMS, 2019-2025
45 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,375 · 2020: $531 · 2021: $866 · 2022: $555 · 2023: $304 · 2024: $358 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $498.02 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $403.19 | 2019-2024 | |
| Pfizer INC. | $364.70 | 2019-2025 | |
| Novo Nordisk INC | $323.94 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.62 | 2019-2021 | |
| Amgen INC. | $247.14 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $198.81 | 2019-2023 | Mounjaro |
| Allergan, INC. | $140.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $130.96 | 2019-2022 | |
| Abbott Laboratories | $124.72 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $109.31 | 2019-2020 | |
| Corcept Therapeutics | $93.79 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.21 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $68.55 | 2019-2021 | |
| Astellas Pharma US INC | $63.96 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Dinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.